Cheddar News

FDA Approves Biogen Produced Alzheimer's Drug Aimed at Slowing Disease

The FDA has approved a new drug, Aducanumab, aimed at slowing Alzheimer's progress in patients. The news comes paired with some controversy after an advisory committee voted against the approval of Biogen's drug due to mixed clinical trial results. Former FDA associate commissioner Peter Pitts joined Cheddar to discuss the groundbreaking news and how Americans might pay for the drug after the manufacturer listed it at an eye-popping $56,000 per treatment.


Latest News

Business & Tech


Who Knew?